Use of bovine serum in the manufacture of human biological medicinal products

Current effective version

PDF iconRevision 1 - Adopted guideline

Reference numberCHMP/BWP/457920/2012 Rev. 1
Effective from01/12/2013
KeywordsBovine serum, adventitious agents, bovine viral diarrhoea virus (BVDV), viral inactivation
DescriptionThis document outlines the general principles that should be applied to the control of the quality and safety of bovine serum used during the manufacture of human biological medicinal products. It applies to vaccines and biotechnological products. It also covers dossier requirements for marketing authorisation applications/variations.

Document history

Revision 1

Current version

PDF iconAdopted guideline

PDF iconOverview of comments

PDF iconDraft guideline

In operation: 01/12/2013–present

Published: 04/06/2013

Published: 01/10/2012

First version PDF iconAdopted guideline In operation: 01/10/2003–01/12/2013

Related content

How useful was this page?

Add your rating